Clinical Trials Browser

Recruiting × INDUSTRY × olaparib × Clear all

NCT06785636 2026-04-22

P300

Phase 1/2 Recruiting

Genital Neoplasms, Male, Neoplasms, Neoplasms by Site, Prostatic Diseases, Prostatic Neoplasms, Urogenital Neoplasms, Male Urogenital Diseases

NCT06353386 2026-04-17

MK-5684-01A

Phase 1/2 Recruiting

Prostatic Neoplasms, Castration-Resistant

NCT06966700 2026-04-17

A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)

Phase 3 Recruiting

Parkinson Disease 4, Autosomal Dominant Lewy Body, Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05238922 2026-04-14

Study of INCB123667 in Subjects With Advanced Solid Tumors

Phase 1 Recruiting

BreastGastrointestinalGynecologic

Carcinoma, Ovarian Epithelial, Breast Neoplasms, Digestive System Neoplasms

NCT03486873 2026-04-13

MK-3475-587

Phase 3 Recruiting

Other hematologic neoplasm

Hematologic Neoplasms

NCT06915025 2026-04-13

OVATION-3

Phase 3 Recruiting

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT07024784 2026-04-06

A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other Therapies

Phase 2 Recruiting

Fallopian Tube Neoplasms, Neoplasms

NCT06797635 2026-03-13

Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)

Phase 2 Recruiting

Breast Neoplasms

NCT07371104 2026-03-05

Bioequivalence Study of DWZ2501 in Patients With Advanced BRCA-mutated High-grade Ovarian Cancer

Phase 1 Recruiting

Neoplasms, Ovarian Neoplasms

NCT02861573 2026-02-17

KEYNOTE-365

Phase 1/2 Recruiting

Metastatic Castration-Resistant Prostate Cancer

NCT04644289 2025-10-03

WoO

Phase 2 Recruiting

Carcinoma, Ovarian Epithelial

NCT05932862 2025-09-05

A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Participants With Advanced Solid Tumors

Phase 1 Recruiting

BreastGastrointestinalGenitourinaryGynecologic

Breast Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms

NCT07069335 2025-07-16

A Bioequivalence Study to Evaluate Pharmacokinetics and Safety of BR2022 and BR2022-1 in Patients With Deleterious or Suspected Deleterious Germline BRCA-Mutated Advanced Ovarian Cancer

Phase 1 Recruiting

Ovarian Neoplasms

NCT06686030 2025-04-16

Combination Therapy of AK112 With Chemotherapy and/or Olaparib in Platinum-sensitive Ovarian Cancer

Phase 2 Recruiting

Platinum-sensitive Ovarian Cancer

NCT05933265 2025-03-06

Study of LP-184 in Patients With Advanced Solid Tumors

Phase 1/2 Recruiting

Neoplasm Metastasis, Neoplasms, Triple Negative Breast Neoplasms

NCT06686745 2025-01-07

Study of SIM0508 Alone and in Combination in Patients With Advanced Solid Tumors

Phase 1 Recruiting

Other solid neoplasm

Advanced Solid Tumors

NCT06525298 2024-09-19

EIS-12656 as Single Agent and in Combination in Patients With Specified Solid Tumors

Phase 1/2 Recruiting

Other solid neoplasm

Advanced Solid Tumor